Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster viewing and lunch

130P - Palbociclib in combination with letrozole in HR+/HER2- residual disease after standard neoadjuvant chemotherapy: primary results of the SOLTI1710 PROMETEO II window of opportunity trial

Date

12 May 2023

Session

Poster viewing and lunch

Presenters

Sonia Pernas Simon

Citation

Annals of Oncology (2023) 8 (1suppl_4): 101220-101220. 10.1016/esmoop/esmoop101220

Authors

S. Pernas Simon1, E. Sanfeliu Torres2, G. Villacampa3, F.J. Salvador Bofill4, A. Perello Martorell5, X. González Farre6, B. Jiménez-Rodríguez7, M. Merino Salvador8, P. Palacios-Ozores9, T. Pascual10, E. Alba11, L. Villanueva12, P. Galván13, A. Prat14, E.M. Ciruelos15

Author affiliations

  • 1 ICO - Institut Català d'Oncologia l'Hospitalet (Hospital Duran i Reynals), L'Hospitalet de Llobregat/ES
  • 2 Hospital Clinic of Barcelona, Barcelona/ES
  • 3 SOLTI - Grupo Espanol de Estudio, 8035 - Barcelona/ES
  • 4 Hospital Universitario Virgen de Valme, 41013 - Seville/ES
  • 5 Hospital Universitario Son Espases, Palma de Mallorca/ES
  • 6 SOLTI / IOR - Instituto Oncologico Dr. Rosell / Hospital General de Catalunya, Barcelona / Sant Cugat del Vallès/ES
  • 7 HUVV - Hospital Universitario Virgen de la Victoria, Malaga/ES
  • 8 Hospital Universitario Infanta Cristina, Parla/ES
  • 9 CHUS - Complejo Hospitalario Universitario de Santiago de Compostela SERGAS, Santiago de Compostela/ES
  • 10 SOLTI / Hospital Clinic of Barcelona, Barcelona/ES
  • 11 Hospital Universitario Virgen de la Victoria, Malaga/ES
  • 12 SOLTI, Barcelona/ES
  • 13 IDIBAPS - Fundació de Recerca Clinic Barcelona - Institut d'Investigacions Biomediques August Pi i Sunyer, 8036 - Barcelona/ES
  • 14 Hospital Clinic y Provincial de Barcelona, Barcelona/ES
  • 15 Hospital Universitario 12 de Octubre, Madrid/ES

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 130P

Background

Studies evaluating adjuvant CDK4/6i provided contradictory results thus far and further characterization of the biological effect of CDK4/6i in residual disease (RD) after neoadjuvant chemotherapy (NAC) is needed. Here we report the primary analysis of the PROMETEO II trial.

Methods

Patients (pts) with HR+/HER2- BC and RD after completing anthracycline/taxane-based NAC were included. RD was confirmed with an ultrasound showing a tumor diameter ≥ 10 mm and a core-biopsy detecting the presence of invasive tumor with Ki67% ≥ 5% by local IHC. Before surgery (SUR), patients received palbociclib 125mg for 21 days and letrozole until SUR. The primary endpoint was complete cell cycle arrest (CCCA) rate determined by Ki67 ≤2.7%, centrally assessed, at SUR. Secondary endpoints include residual cancer burden (RCB) and safety. Tumor samples collected at 3 timepoints (before NAC, during screening (SCR) period and at SUR) were mandatory to assess gene expression, sTILs and PD-L1 IHC (SP142).

Results

22 pts were enrolled: median age 56y (41-69), 45% premenopausal and histologic grade 2/3 63%. The rate of CCCA at SUR was 59% (Table). Between SCR and SUR, Ki67% decreased by a geometric mean change of 44.2%. One patient achieved RCB-I. Intrinsic subtype changes at SUR occurred in 58% of cases, mostly (38.1%) Luminal A/B converting to Normal-like. After palbociclib, immune genes were induced and proliferation genes were suppressed (FDR<5%). Interestingly, immune genes were upregulated in tumors with CCCA after palbociclib compared to tumors with non-CCCA. 9 patients (41%) experienced grade 3 AEs (all neutropenia). Table: 130P

Biomarkers according with the 3 timepoints by central assessment

PRE_NAC SCR SUR
CCCA, n(%) 1 (4) 6 (27) 13(59)
Mean %ki67 22.5 7.2 4.2
sTILs, median (r) 2.5 (<1-35) 2.5 (0-40) 4 (1-20)
PDL1+, n(%) NA 0 3 (14)
IgG high group, n(%) 2 (9) 7 (32) 13 (59)

Conclusions

In chemo-resistant residual disease in pts with HR+/HER2- BC, palbociclib induce a potent anti-proliferative effect. A direct relationship between immune infiltration and anti-proliferative response exists, where immune infiltration is increased in residual tumors with CCCA.

Clinical trial identification

EudraCT 2019-001275-36, NCT04130152 First posted: October 17, 2019.

Legal entity responsible for the study

SOLTI.

Funding

Sponsor: SOLTI Cancer Research Group. This study was funded by Pfizer.

Disclosure

S. Pernas Simon: Financial Interests, Personal, Advisory Board: Seagen, AstraZeneca- Daiichi Sankyo, Pierre-Fabre, Pfizer; Financial Interests, Personal, Invited Speaker: Lilly, Novartis, Eisai, Roche; Financial Interests, Institutional, Invited Speaker: Astra-Zeneca, Novartis, Daiichi Sankyo; Non-Financial Interests, Invited Speaker: SOLTI. G. Villacampa: Financial Interests, Personal, Invited Speaker, Invited speaker in a course: MSD; Financial Interests, Personal, Advisory Board: AstraZeneca; Financial Interests, Personal, Invited Speaker, Invited speaker in an internal training: Pierre Fabrer, GSK; Financial Interests, Personal, Invited Speaker, Internal discussion about the interpretation of some published results: Pfizer; Financial Interests, Personal, Other, Collaborations with specific projects: Reveal Genomics. T. Pascual: Financial Interests, Personal, Invited Speaker: Pfizer/ AstraZeneca / Veracyte / Novartis; Financial Interests, Personal, Advisory Board: Roche/Genentech. A. Prat: Financial Interests, Personal, Invited Speaker: Roche; Financial Interests, Personal, Invited Speaker, Lecture fees: Novartis, Daiichi Sankyo; Financial Interests, Personal, Advisory Board, Advisory role/consultancy: Novartis, Pfizer, Oncolytics Biotech, Guardant Health, Peptomyc; Financial Interests, Institutional, Invited Speaker, Clinical trials: Daiichi Sankyo; Financial Interests, Institutional, Other, Contracted research: Boehringer, Medica Scientia inno. Research; Financial Interests, Personal, Advisory Board: AstraZeneca; Financial Interests, Personal, Invited Speaker, Leadership role: Reveal Genomics, SL.; Financial Interests, Personal, Stocks/Shares: Reveal Genomics, Oncolytics Biotech; Financial Interests, Personal, Royalties: Reveal Genomics; Financial Interests, Institutional, Invited Speaker: Roche, AstraZeneca, Novartis; Financial Interests, Personal and Institutional, Invited Speaker: Daiichi Sankyo; Non-Financial Interests, Institutional, Other, Leadership roles: Patronage committee: SOLTI Foundation, Actitud Frente al Cáncer Foundation; Non-Financial Interests, Personal, Other, Asociación Española de Investigación sobre el Cáncer: ASEICA. E.M. Ciruelos: Financial Interests, Personal, Other, Speakers Bureau. Educational activities: Roche; Financial Interests, Personal, Invited Speaker, Symposia and Educational activities: Roche; Financial Interests, Personal, Advisory Board, Non-permanent advisor: Roche, Lilly, Novartis, Pfizer, Daiichi Sankyo, MSD; Financial Interests, Personal, Invited Speaker, Symposia and Education: Lilly; Financial Interests, Personal, Invited Speaker, Educational activities: Pfizer; Financial Interests, Personal, Advisory Board, Non-permanent advisor, Travel accommodation: AstraZeneca; Financial Interests, Personal, Other, Advisory Board: Gilead; Financial Interests, Personal, Other, Advisory Board, Invited speaker: Seagen; Financial Interests, Institutional, Funding, PI for Patricia 2 trial (sponsor: SOLTI Group): Pfizer; Financial Interests, Institutional, Funding, PI for Prometeo 2 trial (sponsor: SOLTI Group): Pfizer; Financial Interests, Institutional, Funding, PI for TATEN trial (sponsor: SOLTI Group): MSD; Financial Interests, Institutional, Funding, PI for ATREZZO trial (sponsor: SOLTI Group): Roche; Non-Financial Interests, Invited Speaker, Non-profit organization dedicated to breast cancer research: SOLTI Cooperative Group; Non-Financial Interests, Advisory Role, Scientific Evaluator at ISCIII (Spanish Government Academic Research Platform): Instituto de Salud Carlos III. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.